289 related articles for article (PubMed ID: 30341809)
1. The influence of tightening regulations on patients with new psychoactive substance-related disorders in Japan.
Tanibuchi Y; Matsumoto T; Funada D; Shimane T
Neuropsychopharmacol Rep; 2018 Dec; 38(4):189-196. PubMed ID: 30341809
[TBL] [Abstract][Full Text] [Related]
2. [Current situation and clinical characteristics of sedative-related disorder patients in Japan: a comparison with methamphetamine-related disorder patients].
Matsumoto T; Ozaki S; Kobayashi O; Wada K
Seishin Shinkeigaku Zasshi; 2011; 113(12):1184-98. PubMed ID: 22352004
[TBL] [Abstract][Full Text] [Related]
3. [New psychoactive substances abuse among patients with access to methadone maintenance treatment in Jiangsu province: a case-control study].
Cheng Z; Chen GH; Dai MM; Luo W; Lyu P; Cao XB
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 May; 39(5):625-630. PubMed ID: 29860806
[No Abstract] [Full Text] [Related]
4. Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014.
Matsumoto T; Tachimori H; Takano A; Tanibuchi Y; Funada D; Wada K
Psychiatry Clin Neurosci; 2016 Dec; 70(12):560-566. PubMed ID: 27527499
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of quasi-legal psychoactive substance use among male patients in HIV care in Japan: a cross-sectional study.
Hayashi K; Wakabayashi C; Ikushima Y; Tarui M
Subst Abuse Treat Prev Policy; 2017 Feb; 12(1):11. PubMed ID: 28231843
[TBL] [Abstract][Full Text] [Related]
6. The impact of lifetime substance use on psychiatric comorbidities and treatment seeking in patients with alcohol use disorders.
Engelgardt P; Krzyżanowski M; Borkowska-Sztachańska M; Wasilewska A; Ciucias M
Sci Rep; 2024 Jun; 14(1):14257. PubMed ID: 38902395
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of patients with designer-drug-related disorder in Japan: a comparison with patients with methamphetamine- and hypnotic/anxiolytic-related disorders.
Matsumoto T; Tachimori H; Tanibuchi Y; Takano A; Wada K
Psychiatry Clin Neurosci; 2014 May; 68(5):374-82. PubMed ID: 24405505
[TBL] [Abstract][Full Text] [Related]
8. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.
Morgan CJ; Noronha LA; Muetzelfeldt M; Feilding A; Curran HV
J Psychopharmacol; 2013 Jun; 27(6):497-506. PubMed ID: 23438502
[TBL] [Abstract][Full Text] [Related]
9. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
Gillet C; Polard E; Mauduit N; Allain H
Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
[TBL] [Abstract][Full Text] [Related]
10. Limited use of novel psychoactive substances in South London nightclubs.
Wood DM; Hunter L; Measham F; Dargan PI
QJM; 2012 Oct; 105(10):959-64. PubMed ID: 22718853
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of psychoactive substances, alcohol and illicit drugs, in Spanish drivers: A roadside study in 2015.
Domingo-Salvany A; Herrero MJ; Fernandez B; Perez J; Del Real P; González-Luque JC; de la Torre R
Forensic Sci Int; 2017 Sep; 278():253-259. PubMed ID: 28778032
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of use and impairment from drugs and alcohol among trauma patients: A national prospective observational study.
Bråthen CC; Jørgenrud BM; Bogstrand ST; Gjerde H; Rosseland LA; Kristiansen T
Injury; 2023 Dec; 54(12):111160. PubMed ID: 37944451
[TBL] [Abstract][Full Text] [Related]
13. Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France.
Pochard L; Dupouy J; Frauger E; Giocanti A; Micallef J; Lapeyre-Mestre M;
Fundam Clin Pharmacol; 2018 Apr; 32(2):188-197. PubMed ID: 29337399
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of dappou herb use--disorder patients at the drug dependence clinic: a comparison with methamphetamine use-disorder patients].
Tanibuchi Y; Matsumoto T; Kobayashi O; Wada K
Seishin Shinkeigaku Zasshi; 2013; 115(5):463-76. PubMed ID: 23855225
[TBL] [Abstract][Full Text] [Related]
15. Psychoactive drug abuse in older adults.
Simoni-Wastila L; Yang HK
Am J Geriatr Pharmacother; 2006 Dec; 4(4):380-94. PubMed ID: 17296542
[TBL] [Abstract][Full Text] [Related]
16. Psychoactive drug consumption: performance-enhancing behaviour and pharmacodependence in workers.
Ngoundo-Mbongue TB; Niezborala M; Sulem P; Briant-Vincens D; Bancarel Y; Jansou P; Chastan E; Montastruc JL; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):81-9. PubMed ID: 15386725
[TBL] [Abstract][Full Text] [Related]
17. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
Heikman P; Sundström M; Pelander A; Ojanperä I
Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
[TBL] [Abstract][Full Text] [Related]
18. Running away experience and psychoactive substance use among adolescents in Taiwan: multi-city street outreach survey.
Wang SH; Chen WC; Lew-Ting CY; Chen CY; Chen WJ
BMC Public Health; 2010 Jan; 10():29. PubMed ID: 20089181
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
Helander A; Beck O; Hägerkvist R; Hultén P
Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
[TBL] [Abstract][Full Text] [Related]
20. Changes of clinical symptoms in patients with new psychoactive substance (NPS)-related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction.
Funada D; Matsumoto T; Tanibuchi Y; Kawasoe Y; Sakakibara S; Naruse N; Ikeda S; Sunami T; Muto T; Cho T
Neuropsychopharmacol Rep; 2019 Jun; 39(2):119-129. PubMed ID: 30968601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
